Terbutaline + Ambroxol + Guaiphenesin + Menthol

This Syrups formulation occupies the Respiratory and Cough & Cold therapeutic segments, targeting the complete clinical picture of productive cough with airway obstruction. It is a four-molecule combination with no component overlap — each active addresses a pharmacologically distinct aspect of the bronchospasm-mucus-irritation complex:

• Terbutaline Sulphate 1.25mg — selective beta-2 bronchodilator; opens obstructed airways by relaxing bronchial smooth muscle.
• Ambroxol Hydrochloride 15mg — mucolytic; breaks down and thins thick, viscid sputum at the molecular level.
• Guaiphenesin 50mg — expectorant; increases respiratory secretion volume, diluting mucus and facilitating expectoration.
• Menthol 2.5mg — cooling and anti-irritant; desensitizes inflamed upper airway receptors and reduces cough reflex hyperreactivity.

For pharmaceutical marketing companies, this combination is a high-prescriber-confidence respiratory product with year-round demand — peaking in monsoon and winter — and consistent repeat prescription cycles in asthma, COPD, and recurrent bronchitis management. Saar Biotech manufactures it from our facility in Baddi in 60ml and 100ml commercial formats.

At Saar Biotech, we manufacture Terbutaline + Ambroxol + Guaiphenesin + Menthol Syrup using a controlled multi-API liquid homogenization process that addresses the key formulation challenges of this complex combination.

• Four-API Compatibility Engineering: Terbutaline Sulphate, Ambroxol HCl, Guaiphenesin, and Menthol have different solubility profiles and chemical stability requirements in aqueous syrup systems. Our formulation team selects pH buffers, co-solvents, and preservatives that maintain all four actives in a stable, chemically inert matrix for the full 24-month shelf life without cross-degradation.
• Menthol Volatility Control: Menthol is a volatile crystalline compound that can evaporate from open or poorly sealed liquid formulations. Our manufacturing uses closed-vessel compounding and solubilization techniques to ensure Menthol remains in solution at 2.5mg per 5ml throughout the shelf life, retaining the cooling sensation that is a key patient acceptance driver.
• Taste Optimization for High-Ambroxol Load: Ambroxol at 15mg per 5ml carries a noticeable bitter note. Our flavour system — calibrated against the specific bitterness profile of Ambroxol — ensures the finished syrup is commercially palatable for adult and older pediatric populations.
• Consistent High-Volume Batch Production: Our automated liquid filling lines in Baddi are calibrated for both 60ml and 100ml formats, with in-process fill-volume checks ensuring batch-to-batch dose consistency across large seasonal commercial runs.

Terbutaline + Ambroxol + Guaiphenesin + Menthol Syrup is manufactured and supplied by Saar Biotech for the following clinically established indications:

• Bronchial Asthma with Productive Cough: The combination addresses both the bronchospasm (Terbutaline) and the thick mucus plugging (Ambroxol + Guaiphenesin) that characterize asthmatic episodes with productive cough.
• Acute and Chronic Bronchitis: Reduces mucus viscosity, stimulates expectoration, and opens constricted airways — together addressing the complete clinical triad of chest tightness, productive cough, and mucus retention.
• Emphysema and COPD: Adjunctive oral therapy during exacerbations where bronchodilation and enhanced mucociliary clearance are needed alongside primary inhaler regimens.
• Respiratory Tract Infections with Bronchospasm: Post-viral or bacterial bronchitis presentations where airway inflammation has triggered reactive bronchospasm alongside mucus hypersecretion.

Four-Component Pharmacological Synergy

Terbutaline Sulphate binds selectively to beta-2 adrenergic receptors on bronchial smooth muscle. This receptor activation stimulates adenylate cyclase, increasing intracellular cAMP, which causes smooth muscle relaxation and bronchodilation. The selective beta-2 activity minimizes cardiac beta-1 stimulation, making it safer than non-selective sympathomimetics for oral dosing. Orally, 30–50% is absorbed with a half-life of approximately 5.5–6 hours, supporting twice to thrice-daily dosing.

Ambroxol Hydrochloride is the active metabolite of Bromhexine. It inhibits nitric oxide-dependent activation of soluble guanylate cyclase, suppressing excessive mucus glycoprotein secretion. Simultaneously, it stimulates type II pneumocytes to increase surfactant production, reducing the surface tension of the mucus layer and improving its fluidity and clearance by cilia. Protein binding is approximately 90% with a half-life of 7–12 hours.

Guaiphenesin acts primarily as an expectorant via vagal gastric reflex stimulation, triggering an efferent parasympathetic response that increases the volume and reduces the viscosity of bronchial secretions. This dilutes thick mucus, making it more amenable to mucociliary transport and productive expectoration.

Menthol activates TRPM8 cold-sensitive receptor channels in the oropharyngeal and nasopharyngeal mucosa, producing a soothing cooling effect that reduces the hypersensitivity of irritated cough-reflex pathways. It also demonstrates kappa-opioid receptor agonism, contributing mild peripheral analgesic activity to soothe inflamed airway mucosa.

Manufacturing Integrity

• Terbutaline pH Stability: Terbutaline Sulphate is susceptible to oxidative degradation in alkaline environments. Our formulation maintains the syrup vehicle within a validated mildly acidic pH range that protects Terbutaline’s chemical integrity throughout the shelf life without compromising Ambroxol or Guaiphenesin stability.
• Menthol Solubilization: Menthol’s crystalline nature requires complete dissolution in a compatible co-solvent before incorporation into the aqueous syrup base. Our sequential compounding protocol ensures Menthol is fully solubilized and uniformly dispersed, preventing recrystallization within the bottle over time.

• Complementary Onset Profiles: Terbutaline’s bronchodilatory effect begins within 30–60 minutes of oral dosing. Ambroxol reaches peak plasma concentration within 1–3 hours, with mucolytic activity evident after repeat dosing. This sequential onset — bronchial opening followed by mucus thinning and clearance — creates a progressive clinical improvement that patients and prescribers clearly notice, supporting brand loyalty.
• Three-Times-Daily Convenience: Terbutaline’s 5–6 hour half-life aligns with Ambroxol’s 7–12 hour half-life and Guaiphenesin’s 1-hour activity window (requiring more frequent dosing) to support a practical thrice-daily regimen. This dosing convenience is a commercial advantage for brands competing in the respiratory syrup segment.
• Menthol as a Sensory Brand Signal: The immediate cooling sensation of Menthol 2.5mg is perceptible from the first dose — a distinctive sensory signal that patients associate with airway relief. This cooling characteristic can be a strong brand differentiator in a category where many competing products lack this distinctive sensory element.
• 60ml and 100ml Pack Coverage: The 60ml format covers a shorter acute course (3–5 days at standard dosing). The 100ml format suits the 7–10 day courses typically prescribed for bronchitis and acute COPD exacerbations. Together, they allow brands to address both acute and extended respiratory treatment segments.

Saar Biotech offers comprehensive Contract Manufacturing (CMO) and Third-Party Manufacturing for Terbutaline + Ambroxol + Guaiphenesin + Menthol Syrup from our oral liquid manufacturing facility in Baddi, Himachal Pradesh.

• Facility: Dedicated liquid manufacturing block with controlled compounding vessels, automated filling lines, and inline pH and viscosity monitoring.
• Capacity: Scalable from 5,000-unit brand-entry batches to 2,00,000+ unit seasonal commercial runs; 120×100ml and 144×100ml shipper configurations available.
• Quality Lab: In-house GLP-certified lab with multiplex HPLC for four-active assay, pH meters, viscometers, MLT capability, and stability chambers.
• Turnaround: New orders — 30 to 45 working days. Repeat orders — 20 to 25 working days.
• Packaging: 60ml and 100ml amber PET bottles; sticker label, metallic label, Drip-off Embossed carton, silver leafing, tricolour measuring cap, printed cap, company-logo cap; with/without carton options.
• MOQ: 5,000–10,000 units per SKU.

1. Temperature Control: Store below 30°C in a cool, dry place. Elevated temperatures accelerate Terbutaline oxidative degradation and can cause Menthol to partially evaporate from the syrup base if bottles are poorly sealed — making proper cap torque and upright storage critical.
2. Light Protection: Terbutaline Sulphate is sensitive to UV degradation. Amber PET bottles provide essential protection; outer cartons must remain intact during distribution and retail storage to prevent prolonged light exposure.
3. Closure Integrity: Menthol’s volatility means loosely capped bottles will progressively lose Menthol content over time, reducing the cooling effect. Pilfer-proof closures are applied at the factory; patients should replace caps securely after every use.
4. No Freezing: Sub-zero temperatures can cause Menthol to crystallize out of solution and alter the syrup base viscosity. The product does not require cold-chain logistics.

Every commercial batch is quarantined and released only after a complete analytical battery in our GLP-certified QC laboratories in Baddi:

• Four-Active HPLC Assay: Simultaneous or sequential HPLC quantification of Terbutaline Sulphate, Ambroxol HCl, and Guaiphenesin per IP specifications; Menthol assay by GC or validated method. All actives confirmed at 98–102% of label claim.
• pH Mapping: Confirmed within the validated stability range for all four actives.
• Viscosity Testing: Syrup consistency verified for correct pourability and accurate dose delivery from measuring cap.
• Microbial Limit Testing (MLT): IP oral liquid standard testing confirming absence of specified pathogens.
• Fill Volume Accuracy: In-process and final fill-volume checks across both 60ml and 100ml pack sizes.
• Certificate of Analysis (COA): Issued with every B2B batch dispatch.

This combination is generally well tolerated at recommended doses. Most adverse effects are related to Terbutaline’s beta-agonist activity and include fine hand tremors, palpitations, and mild tachycardia — particularly at the start of therapy. Headache, mild nausea, and dizziness have been reported. Severe nausea, vomiting, or skin rash should prompt medical review.

Terbutaline is contraindicated in severe cardiovascular disorders. Use with caution in hyperthyroidism, diabetes, and hepatic impairment. Co-administration with non-selective beta-blockers reduces bronchodilator efficacy. Not recommended for self-medication in children without physician direction.

For B2B manufacturing enquiries, third-party contracts, or to request pricing and packaging options for Terbutaline + Ambroxol + Guaiphenesin + Menthol Syrup, please use the enquiry form below.